Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Viracta Therapeutics: Q3 Earnings Insights

Viracta Therapeutics (NASDAQ:VIRX) reported its Q3 earnings results on Thursday, November 9, 2023 at 08:30 AM. Here’s what…
byBenzinga Insights
November 9, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Viracta Therapeutics (NASDAQ:VIRX) reported its Q3 earnings results on Thursday, November 9, 2023 at 08:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Viracta Therapeutics missed estimated earnings by 10.0%, reporting an EPS of $-0.33 versus an estimate of $-0.3.

Revenue was down $0 from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.04 which was followed by a 7.8% drop in the share price the next day.

** Listen to the earnings announcement yourself by clicking here. **

To track all earnings releases for Viracta Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

cbdMD Reports YoY Dip In Q1 Net Sales, Shrinks Operating Loss, Expands Into Hemp And Mushroom Products Markets

By Jelena Martinovic
February 14, 11:03 AM
Medical cannabis company cbdMD has reported financial results for its first quarter of fiscal 2024. Operating loss improved to $1.1m compared to $4.1m for the same period in the previous year. Gross profit was flat at around $3.5m, while operating expenses were $4.6m, down from $7.6m in the previous year. Total net sales declined to $5.37m from almost $6m in the corresponding prior-year period. Direct-to-consumer net sales represented 82.3% of total net sales, a decrease from 90% in Q1 2023. On 31 December 2023, cbdMD had total working capital of roughly $1.4m compared to approximately $3.4m on 30 September, with cash on hand dropping to roughly $1.5m from $1.8m over the same period. The Charlotte-based company recently struck a securities purchase agreement with five institutional investors to fund the national rollout of its ATRx Labs functional mushroom products, as well as launching the hempMD and ATRx Labs brands.

YCBD